ABSTRACT
Juvenile MS, is widely prevalent in developing regions of the world with prevalence as high as 25% of all MS patients. After an initial attack of rheumatic fever, the disease progresses rapidly and patients may develop severe stenosis within 3-5 years. These patients present in advanced functional class and have evidence of severe pulmonary hypertension. The majority of juvenile MS patients, continue to maintain sinus rhythm and thromboembolic episodes are uncommon. If valve morphology is suitable PTMC should be the first treatment offered. It provides good short term and long-term outcomes. Finally, with improvement of socioeconomic conditions and appropriate healthcare delivery, the prevalence of juvenile MS can be decreased.
